ニューヨークにおける脂肪肝の臨床試験
ニューヨーク内の拠点で、脂肪肝に関する17件の研究が参加者を募集しています。
ニューヨーク内の都市
公式研究テキスト（英語）
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, New York
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- New York Presbyterian/Weill Cornell, New York
- Columbia University Iriving School of Medicine, New York
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Columbia University Irving Medical Center, New York
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Research Foundation of SUNY - University of Buffalo, Buffalo
- NYU Langone Health, New York
- IMA Clinical Research Manhattan, New York
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Buffalo
- Akero Clinical Study Site, Manhasset
- Akero Clinical Study Site, New York
- 他3件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, Carmel
- 89bio Clinical Study Site, New York
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, New York
- 89bio Clinical Study Site, New York
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/03更新 · NCT06419374Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Columbia University Irving Medical Center, New York
被験者募集中第1相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/08/24更新 · NCT06354088A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, New York
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/08/03更新 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
- GSK Investigational Site, New York
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, New York
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/07/08更新 · NCT06920043Effect of Insulin Lowering on Lipogenesis
- Columbia University Irving Medical Center, New York
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/07/06更新 · NCT07403604Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Icahn School of Medicine at Mount Sinai, New York
被験者募集中
18歳〜75歳 · 全性別 · 2026/05/19更新 · NCT04054310Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
- Weill Cornell Medicine, New York
被験者募集中健康なボランティア歓迎
18歳〜65歳 · 全性別 · 2026/02/27更新 · NCT05332613High Fructose Diet, the Gut Microbiome, and Metabolic Health
- Mount Sinai Morningside, New York
被験者募集中健康なボランティア歓迎
25歳〜45歳 · 全性別 · 2025/12/17更新 · NCT06329544Blood Collection Biorepository for Liver Disease Research
- University at Buffalo, Buffalo General Medical Center, Buffalo
被験者募集中観察研究健康なボランティア歓迎
7歳以上 · 全性別 · 2025/08/27更新 · NCT03025074ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。